87 related articles for article (PubMed ID: 12704661)
1. Glutathione peroxidase isoforms as part of the local antioxidative defense system in normal and Barrett's esophagus.
Mörk H; Scheurlen M; Al-Taie O; Zierer A; Kraus M; Schöttker K; Jakob F; Köhrle J
Int J Cancer; 2003 Jun; 105(3):300-4. PubMed ID: 12704661
[TBL] [Abstract][Full Text] [Related]
2. Differences in ERK activation in squamous mucosa in patients who have gastroesophageal reflux disease with and without Barrett's esophagus.
Souza RF; Shewmake KL; Shen Y; Ramirez RD; Bullock JS; Hladik CL; Lee EL; Terada LS; Spechler SJ
Am J Gastroenterol; 2005 Mar; 100(3):551-9. PubMed ID: 15743351
[TBL] [Abstract][Full Text] [Related]
3. MicroRNA-143 and -205 expression in neosquamous esophageal epithelium following Argon plasma ablation of Barrett's esophagus.
Dijckmeester WA; Wijnhoven BP; Watson DI; Leong MP; Michael MZ; Mayne GC; Bright T; Astill D; Hussey DJ
J Gastrointest Surg; 2009 May; 13(5):846-53. PubMed ID: 19190970
[TBL] [Abstract][Full Text] [Related]
4. Expression of glutathione s-transferase pi in benign mucosa, Barrett's metaplasia, and adenocarcinoma of the esophagus.
Chandra RK; Bentz BG; Haines GK; Robinson AM; Radosevich JA
Head Neck; 2002 Jun; 24(6):575-81. PubMed ID: 12112555
[TBL] [Abstract][Full Text] [Related]
5. Glutathione peroxidase 7 protects against oxidative DNA damage in oesophageal cells.
Peng D; Belkhiri A; Hu T; Chaturvedi R; Asim M; Wilson KT; Zaika A; El-Rifai W
Gut; 2012 Sep; 61(9):1250-60. PubMed ID: 22157330
[TBL] [Abstract][Full Text] [Related]
6. The expression of 8-hydroxydeoxyguanosine in oesophageal tissues and tumours.
Räsänen JV; Sihvo EI; Ahotupa MO; Färkkilä MA; Salo JA
Eur J Surg Oncol; 2007 Dec; 33(10):1164-8. PubMed ID: 17467227
[TBL] [Abstract][Full Text] [Related]
7. Aurora kinase A in Barrett's carcinogenesis.
Rugge M; Fassan M; Zaninotto G; Pizzi M; Giacomelli L; Battaglia G; Rizzetto C; Parente P; Ancona E
Hum Pathol; 2010 Oct; 41(10):1380-6. PubMed ID: 20656315
[TBL] [Abstract][Full Text] [Related]
8. Increased c-myb mRNA expression in Barrett's esophagus and Barrett's-associated adenocarcinoma.
Brabender J; Lord RV; Danenberg KD; Metzger R; Schneider PM; Park JM; Salonga D; Groshen S; Tsao-Wei DD; DeMeester TR; Hölscher AH; Danenberg PV
J Surg Res; 2001 Aug; 99(2):301-6. PubMed ID: 11469901
[TBL] [Abstract][Full Text] [Related]
9. Predictors for squamous re-epithelialization of Barrett's esophagus after endoscopic biopsy.
Amano Y; Kushiyama Y; Yuki T; Takahashi Y; Chinuki D; Ishimura N; Furuta K; Ishihara S; Adachi K; Maruyama R; Kinoshita Y
J Gastroenterol Hepatol; 2007 Jun; 22(6):901-7. PubMed ID: 17565646
[TBL] [Abstract][Full Text] [Related]
10. Cyclooxygenase-2 (COX-2) is the key event in pathophysiology of Barrett's esophagus. Lesson from experimental animal model and human subjects.
Majka J; Rembiasz K; Migaczewski M; Budzynski A; Ptak-Belowska A; Pabianczyk R; Urbanczyk K; Zub-Pokrowiecka A; Matlok M; Brzozowski T
J Physiol Pharmacol; 2010 Aug; 61(4):409-18. PubMed ID: 20814068
[TBL] [Abstract][Full Text] [Related]
11. Expression of CD44v5 and -v6 in Barrett's carcinoma is not increased compared to that in nondysplastic Barrett's mucosa.
Menges M; Goebel R; Pueschel W; Zeitz M; Stallmach A
Exp Mol Pathol; 2002 Jun; 72(3):207-12. PubMed ID: 12009784
[TBL] [Abstract][Full Text] [Related]
12. Survivin, a potential biomarker in the development of Barrett's adenocarcinoma.
Vallböhmer D; Peters JH; Oh D; Kuramochi H; Shimizu D; Demeester SR; Hagen JA; Chandrasoma PT; Danenberg KD; DeMeester TR; Danenberg P
Surgery; 2005 Oct; 138(4):701-6; discussion 706-7. PubMed ID: 16269299
[TBL] [Abstract][Full Text] [Related]
13. Risk factors, DNA damage, and disease progression in Barrett's esophagus.
Olliver JR; Hardie LJ; Gong Y; Dexter S; Chalmers D; Harris KM; Wild CP
Cancer Epidemiol Biomarkers Prev; 2005 Mar; 14(3):620-5. PubMed ID: 15767340
[TBL] [Abstract][Full Text] [Related]
14. Proinflammatory cytokine and nuclear factor kappa-B expression along the inflammation-metaplasia-dysplasia-adenocarcinoma sequence in the esophagus.
O'Riordan JM; Abdel-latif MM; Ravi N; McNamara D; Byrne PJ; McDonald GS; Keeling PW; Kelleher D; Reynolds JV
Am J Gastroenterol; 2005 Jun; 100(6):1257-64. PubMed ID: 15929754
[TBL] [Abstract][Full Text] [Related]
15. High recurrence rate of Barrett's epithelium during long-term follow-up after argon plasma coagulation.
Mörk H; Al-Taie O; Berlin F; Kraus MR; Scheurlen M
Scand J Gastroenterol; 2007 Jan; 42(1):23-7. PubMed ID: 17190758
[TBL] [Abstract][Full Text] [Related]
16. Advanced pathology under squamous epithelium on initial EMR specimens in patients with Barrett's esophagus and high-grade dysplasia or intramucosal carcinoma: implications for surveillance and endotherapy management.
Chennat J; Ross AS; Konda VJ; Lin S; Noffsinger A; Hart J; Waxman I
Gastrointest Endosc; 2009 Sep; 70(3):417-21. PubMed ID: 19555948
[TBL] [Abstract][Full Text] [Related]
17. Squamous islands in Barrett's esophagus: what lies underneath?
Sharma P; Morales TG; Bhattacharyya A; Garewal HS; Sampliner RE
Am J Gastroenterol; 1998 Mar; 93(3):332-5. PubMed ID: 9517634
[TBL] [Abstract][Full Text] [Related]
18. Review article: management of oesophageal adenocarcinoma -- control of acid, bile and inflammation in intervention strategies for Barrett's oesophagus.
Jankowski JA; Anderson M
Aliment Pharmacol Ther; 2004 Oct; 20 Suppl 5():71-80; discussion 95-6. PubMed ID: 15456468
[TBL] [Abstract][Full Text] [Related]
19. Inverse mRNA expression of the selenocysteine-containing proteins GI-GPx and SeP in colorectal adenomas compared with adjacent normal mucosa.
Mörk H; al-Taie OH; Bähr K; Zierer A; Beck C; Scheurlen M; Jakob F; Köhrle J
Nutr Cancer; 2000; 37(1):108-16. PubMed ID: 10965527
[TBL] [Abstract][Full Text] [Related]
20. Distribution of laminins in the basement membranes of the upper gastrointestinal tract and Barrett's oesophagus.
Dave U; Thursz MR; Ebrahim HY; Burke MM; Townsend ER; Walker MM
J Pathol; 2004 Mar; 202(3):299-304. PubMed ID: 14991894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
